Quality of life in patients with neovascular age-related macular degeneration before and after intravitreal therapy: a longitudinal observational study - Summary - MDSpire
Advertisement
Quality of life in patients with neovascular age-related macular degeneration before and after intravitreal therapy: a longitudinal observational study
To examine vision-related quality of life in individuals with neovascular age-related macular degeneration prior to treatment and following a course of seven intravitreal injections, and to analyze its association with visual acuity, contrast sensitivity, and specific visual disturbances such as metamorphopsia and central scotoma.
Key Findings:
121 patients (121 eyes) participated, with a mean age between 51 and 90 years.
Statistically significant improvement in vision-related quality of life was observed post-treatment.
Quality of life was associated with visual function parameters such as visual acuity and contrast sensitivity.
Interpretation:
Vision-related quality of life was low at baseline and showed modest improvement following intravitreal anti-VEGF therapy. Higher quality of life scores correlated with better visual acuity, higher contrast sensitivity, and fewer visual disturbances.
Limitations:
The study did not address long-term effects beyond the follow-up period.
Potential biases in self-reported quality of life measures.
The short follow-up period may limit the understanding of long-term benefits.
Conclusion:
The study highlights the potential psychosocial benefits of intravitreal therapy in neovascular age-related macular degeneration.
